Alphabet Inc (GOOGL) · Earnings Release

Adaptive Biotechnologies Corp (ADPT) · Earnings Release

First quarter 2026 earnings release scheduled.

5/6/2026, 12:00:00 AM

Recursion Pharmaceauticals Inc (RXRX) · Earnings Release

Q1 2026 earnings release is scheduled. Analysts forecast an EPS of -$0.27, forecasted and scheduled. A low impact is estimated as the market typically reacts to actual results.

5/4/2026, 12:00:00 AM

AbbVie Inc (ABBV) · Earnings Release

AbbVie is scheduled to release its Q1 2026 financial results on April 24, 2026, with analysts forecasting EPS around $3.01-$3.02 and revenue of approximately $14.72 billion; Medium importance is estimated based on typical earnings price impact, scheduled.

4/24/2026, 12:00:00 AM

Caris Life Sciences Inc (CAI) · Other

Began presenting five studies at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting from March 23-24, 2026, showcasing new data across multiple cancer types. Low importance is estimated as scientific presentations typically result in a ≥1% price impact, scheduled.

3/23/2026, 12:00:00 AM

Eli Lilly and Co (LLY) · Other

Eli Lilly announced positive top-line results from its TRANSCEND-T2D-1 Phase 3 trial for retatrutide, a next-generation obesity and diabetes drug. The study showed significant reductions in both A1C levels and body weight in adults with type 2 diabetes, expected. High importance is estimated as positive Phase 3 results for a major drug typically result in a price impact exceeding 10%.

3/19/2026, 12:00:00 AM

AbbVie Inc (ABBV) · Other

AbbVie's stock price declined on March 18, 2026, following FDA approvals in early March for competitor immunology drugs from Johnson & Johnson (ICOTYDE) and Bristol Myers Squibb (Sotyktu), increasing competition for AbbVie's products.

3/18/2026, 12:00:00 AM